Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;18(2):93-103.
doi: 10.1038/s41585-020-00394-5. Epub 2020 Nov 25.

The biology and rationale of targeting nectin-4 in urothelial carcinoma

Elisabeth I Heath  1 , Jonathan E Rosenberg  2   3
Affiliations
Review

The biology and rationale of targeting nectin-4 in urothelial carcinoma

Elisabeth I Heath et al. Nat Rev Urol. 2021 Feb.

Abstract

Bladder cancer is the tenth most common cancer type worldwide. Urothelial carcinoma is the most common type of bladder cancer and accounts for 90% of bladder cancer cases in the USA and Europe. Novel approaches are needed to improve patient outcomes. Nectin-4 is a tumour-associated antigen found on the surface of most urothelial carcinoma cells. In the antibody-drug conjugate enfortumab vedotin, human anti-nectin-4 antibody is linked to the cytotoxic microtubule-disrupting agent monomethyl auristatin E. In ongoing phase I, II and III clinical trials, enfortumab vedotin has been evaluated as a monotherapy and in combination with a checkpoint inhibitor and/or chemotherapy in locally advanced and metastatic urothelial carcinoma. Encouraging data from the phase II study resulted in the FDA granting accelerated approval for enfortumab vedotin in December 2019 for patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum and a checkpoint inhibitor therapy. Moreover, data from a phase I study led to the FDA granting breakthrough therapy designation to enfortumab vedotin combined with pembrolizumab as a first-line treatment in February 2020 for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. Results of ongoing and future combination studies of enfortumab vedotin with immunotherapy and other novel agents are eagerly awaited.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018). - PubMed - DOI
    1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020). - PubMed - DOI
    1. Cancer.Net Editorial Board. Bladder cancer: statistics. Cancer.Net https://www.cancer.net/cancer-types/bladder-cancer/statistics (2020).
    1. American Cancer Society. Survival rates for bladder cancer. American Cancer Society https://www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging... (2020).
    1. Flaig, T. W. et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 18, 329–354 (2020). - PubMed - DOI

Publication types

MeSH terms

LinkOut - more resources